地拉罗司适合什么人用？

(Deferasirox) is currently the only oral iron ion chelator. Iron chelator is a new type of iron removal treatment based on directional binding with iron ions in the body, effectively increasing iron excretion, reducing iron content in the body and its pathological deposition in various organs. It is also the only effective drug currently used to treat iron overload. The application of iron chelators has greatly reduced the mortality and improved the quality of life of patients with long-term blood transfusions, and its clinical application has been receiving widespread attention and attention. The launch of Deferasirox (deferasirox) has also attracted much attention from patients. So, who is suitable for deferasirox (deferasirox)?

The indications for Deferasirox are:

1. Patients with chronic iron overload transfusion hemosiderinosis secondary to blood transfusion who are 2 years old or older will develop symptoms of chronic iron overload when serum ferritin continues to be >1000 L. At this time, iron chelation therapy should be started.

2. Can be used to treat reversible renal insufficiency caused by Fanconi syndrome.

3. Patients receiving ASCT can also be given iron chelator therapy when iron overload occurs;

Deferasirox is a tridentate iron chelator that combines with ferric iron ions in a 2:1 ratio to form a complex that is excreted in the feces, thereby reducing iron storage in the body. Because Deferasirox continues to exist in plasma, it can continuously reduce plasma non-transferrin-bound iron and directly remove iron formed from toxicity in the body.

The common starting dose of Deferasirox is 20 mg/(kg·d). If there is a large amount of blood transfusion and the iron increase is >0.5 mg/(kg·d) or the iron load before treatment is high, the recommended dose is 30 mg/(kg·d). If the iron increase is <0.3 mg/kg, 10-15 mg/kg/d is enough to control the disease. Administer on an empty stomach 30 minutes before meals and should be completely dissolved in water or apple or orange juice.

Lower doses of Deferasirox (5-10 mg/(kg·d)) can only be used in young patients with mild iron overload and few blood transfusions, or in elderly patients who have not received satisfactory results from chelation therapy in the past; patients using Deferasirox 20 and 30 mg/(kg·d) need to carefully monitor body iron stores, because body iron levels may continue to rise in 50% and 10% of patients.

In addition, the frequency of blood transfusion can also affect the effect of Deferasirox (Deferasirox) in controlling liver concentrations. When the iron intake is greater than 0.5 mg/(kg·d), only 47% of patients who receive the same dose of Deferasirox (Deferasirox) achieve a reduction in liver concentrations.

The above is the content of the indications of Deferasirox, I hope it can help you!